Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Oravig is the first and only muco-adhesive buccal tablet formulation of miconazole approved to treat oropharyngeal candidiasis (OPC), also known as oral thrush, in adult patients in the United States.
Lead Product(s): Miconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Oravig
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Fortovia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 16, 2020
Details:
U.S. Food and Drug Administration approved the company’s Supplemental Abbreviated New Drug Application for Orphengesic Forte, over two months ahead of the scheduled goal date.
Lead Product(s): Orphenadrine,Aspirin,Caffeine
Therapeutic Area: Neurology Product Name: Orphengesic Forte
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020